Trifluoperazine, originally marketed as Stelazine by SmithKline & French in the late 1950s, is a piperazine phenothiazine antipsychotic. Within the phenothiazine family, drugs are grouped by side chain: aliphatic (chlorpromazine), piperidine (thioridazine), and piperazine (fluphenazine, perphenazine, trifluoperazine). The piperazine phenothiazines tend to be high-potency — strong D2 blockade per milligram, lower sedation, less anticholinergic burden, more EPS. Trifluoperazine fits that pattern.
Trifluoperazine is a high-potency piperazine phenothiazine approved for schizophrenia and short-term anxiety, with strong D2 blockade, low sedation, and a meaningful risk of movement side effects.
FDA-approved indications
Per the DailyMed trifluoperazine label, US-approved uses include:
- Management of schizophrenia
- Short-term treatment of generalised non-psychotic anxiety in adults — explicitly limited to a maximum of 12 weeks and only when other treatments have not worked
The anxiety indication is unusual in modern antipsychotic labelling and reflects 1950s practice when phenothiazines were used broadly for "tension states." Today few prescribers use trifluoperazine for anxiety, given the side effect profile and the availability of safer alternatives.
How it works
Strong D2 receptor blockade drives the antipsychotic effect. Compared with low-potency phenothiazines, trifluoperazine has weaker affinity for histamine H1, muscarinic, and alpha-1 adrenergic receptors, which is why doses are in the milligrams (not hundreds of milligrams) and why sedation, dry mouth, and orthostatic dizziness are less prominent.
Typical dosing
Per the FDA label, schizophrenia doses generally range from 4 to 40 mg per day in divided doses, occasionally higher in inpatient settings. Anxiety doses are much lower (1 to 2 mg twice daily, not exceeding 6 mg per day, with the 12-week maximum).
Side effects
Movement effects
Acute dystonia, parkinsonism, and akathisia are common, particularly in the first weeks. Anticholinergic medications such as benztropine are sometimes co-prescribed. Tardive dyskinesia risk accumulates with long-term use.
Sedation
Mild to moderate. Generally less than with chlorpromazine.
Hyperprolactinemia
Like other potent D2 blockers, trifluoperazine raises prolactin, which can cause menstrual changes, breast changes, sexual dysfunction, and over time bone density concerns.
Anticholinergic effects
Generally mild — less dry mouth, constipation, blurred vision than with low-potency phenothiazines.
Cardiovascular
QT prolongation can occur, particularly at higher doses or with other QT-prolonging drugs. Orthostatic hypotension is less marked than with chlorpromazine but possible.
Hepatic and haematologic
Cholestatic jaundice and rare blood dyscrasias have been reported as class effects. Periodic monitoring is reasonable.
Photosensitivity and pigmentation
Sun sensitivity is a phenothiazine class effect. Sunscreen and protective clothing are recommended.
Severe muscle stiffness with high fever and confusion, sudden severe involuntary movements, or signs of an allergic reaction.
Boxed warning
The standard antipsychotic boxed warning applies — increased mortality in elderly patients with dementia-related psychosis.
Drug interactions
Additive sedation with CNS depressants. Additive QT effects with other QT-prolonging drugs. Lowered seizure threshold, relevant when combined with bupropion or tramadol. Anticholinergic effects compound those of other anticholinergics. Always disclose all medications and supplements.
Where trifluoperazine fits in 2026
Like other older typical antipsychotics, trifluoperazine has been displaced from first-line use by second-generation agents. It retains a role in:
- Patients who have responded well historically and want to continue
- Cost-constrained settings where generics dominate
- Cases where the clinician wants high-potency D2 blockade without the metabolic burden of olanzapine or quetiapine
- International settings where trifluoperazine remains widely available and cheap
It is not currently a first-choice agent for new patients in most high-income settings.
Practical questions to ask your prescriber
- Why trifluoperazine rather than a newer drug?
- What is the plan for monitoring movement side effects?
- Should I be on an anticholinergic prophylactically or only as needed?
- What baseline ECG, weight, prolactin, and labs do I need?
The big picture
Trifluoperazine is a working drug with decades of clinical experience behind it. For patients who tolerate it and respond, it can be a stable foundation. For new patients, the modern preference is for second-generation antipsychotics with lower EPS burden. The decision is best worked out with a prescriber familiar with your full history.
This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling, regulatory sources, and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication.